There are several ongoing trials to assess different immunotherapy agents in renal cell carcinoma as detailed below.
| Immunotherapy Agent | Treatment | Phase | Clinicaltrials.gov identifier |
| Anti-CTLA4 | |||
| Ipilimumab | Ipilimumab | II | NCT00057889 |
| Anti-PD-1 | |||
| Nivolumab
(BMS-936558) |
Nivolumab + Sunitinib
Nivolumab + Pazopanib Nivolumab + Ipilimumab |
I | NCT01472081 |
| Nivolumab + Temsirolimus
Nivolumab + Irinotecan (Chemotherapy) Nivolumab + Irinotecan/Capecitabine |
I/II | NCT02423954 | |
| Nivolumab (varied dose) | II | NCT01354431 | |
| Nivolumab
Nivolumab + Bevacizumab Nivolumab + Ipilmumab |
II | NCT02210117 | |
| Nivolumab + Ipilimumab vs Sunitinib | III | NCT02231749 | |
| Nivolumab vs Everolimus | III | NCT01668784 | |
| Pembrolizumab
(MK-3475) |
Pembrolizumab vs Pazopanib
Pembrolizumab + Pazopanib vs Pazopanib |
I | NCT02014636
|
| Pembrolizumab + Radiation therapy | I | NCT02318771 | |
| Pembrolizumab + Axitinib | I | NCT02133742 | |
| Pembrolizumab + surgical resection | I | NCT02212730 | |
| Pembrolizumab + Ziv-Aflibercept | I | NCT02298959 | |
| Pembrolizumab + Bevacizumab | I/II | NCT02348008 | |
| Pembrolizumab
Pembrolizumab + Ipilimumab Pembrolizumab + Pegylated IFN-2b |
I/II | NCT02089685 | |
| Pidilizumab
(CT-011) |
Pidilizumab
Pidilizumab + Dendritic Cell (DC) vaccine |
II | NCT01441765 |
| Anti-PD-L1 | |||
| MPDL-3280A | MPDL vs Sunitinib
MPDL + Bevacizumab vs Sunitinib |
II | NCT01984242 |
| III | NCT02420821 | ||
| Dendritic cell vaccine | |||
| AGS-003 | AGS-003 + surgical resection | I | NCT02170389 |
| AGS-003 | I/II | NCT00272649 | |
| AGS-003 + Sunitinib | II | NCT00678119 | |
| AGS-003 vs AGS-003 + Sunitinib | II | NCT01482949 | |
| AGS-003 + Sunitinib vs Sunitinib | III | NCT01582672 | |
| Multi-peptide vaccine | |||
| IMA901 | IMA901 + Sunitinib vs Sunitinib | III | NCT01265901 |